Abstract
In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.
| Original language | Danish |
|---|---|
| Article number | V11170870 |
| Journal | Ugeskrift for Laeger |
| Volume | 181 |
| Issue number | 7 |
| ISSN | 0041-5782 |
| Publication status | Published - 2019 |
Fingerprint
Cite this
}
Behandling af synstruende diabetisk retinopati. / Grauslund, Jakob.
In: Ugeskrift for Laeger, Vol. 181, No. 7, V11170870, 2019.Research output: Contribution to journal › Journal article › Research › peer-review
TY - JOUR
T1 - Behandling af synstruende diabetisk retinopati
AU - Grauslund, Jakob
PY - 2019
Y1 - 2019
N2 - In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.
AB - In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.
KW - Angiogenesis Inhibitors/administration & dosage
KW - Anti-Inflammatory Agents/administration & dosage
KW - Diabetes Mellitus, Type 1/complications
KW - Diabetes Mellitus, Type 2/complications
KW - Diabetic Retinopathy/drug therapy
KW - Humans
KW - Intravitreal Injections
KW - Laser Coagulation
KW - Macular Edema/drug therapy
M3 - Tidsskriftartikel
VL - 181
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 7
M1 - V11170870
ER -